Activity of isavuconazole and comparator agents against pediatric isolates from invasive fungal infections

Clicks: 18
ID: 320344
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #12 of 40 articles by views in journal of the pediatric infectious diseases society

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Invasive fungal infections (IFI) are a rising problem among pediatric patients. Antifungal agents have data supporting treatment in pediatric patients of varying ages and infection types but in vitro susceptibility data for large collections of pediatric isolates is lacking, which limits empiric treatment. We describe in vitro antifungal susceptibility testing (AFST) of 900 contemporary yeast and mold isolates collected from IFI in patients ≤17 years of age as a part of the SENTRY Antifungal Surveillance Program. Methods 900 isolates (743 yeast and 157 molds) were collected from 28 countries between 2017 and 2024. AFST was performed by broth microdilution (BMD) according to Clinical Laboratory and Standards Institute (CLSI) methodology. Results 33.4% of isolates were from patients ≤1 year old, 22.1% from 2–5 years old, 24.4% from 6–12 years old, and 20.0% from 13-17 years old. 63.0% of yeasts were recovered in patients ≤5 years old; 79.6% of molds were in patients ≥6 years old. Most yeast isolates (72.5%) were from bloodstream infections; most mold isolates (61.8%) were from the respiratory tract. By CLSI breakpoints, 88.5% and 87.5% of Aspergillus fumigatus were susceptible to voriconazole and isavuconazole, respectively. Against Mucorales, isavuconazole MIC50 was 4 mg/L and >8 mg/L for voriconazole and posaconazole. All agents had low MICs to most yeasts collected and there were few resistant or non-wildtype yeasts. Conclusions BMD among a diverse collection of isolates obtained from IFI among pediatric patients showed low rates of resistance to echinocandins or azoles. Across species, the lowest MICs were observed for voriconazole and isavuconazole in yeasts. All triazoles were highly active against Aspergillus spp. Against non-Aspergillus molds, isavuconazole, posaconazole, and amphotericin B were the most active agents. This data can guide antifungal treatment of IFI in pediatric patients when susceptibility testing is unavailable.
Reference Key
openalex_W7167822819 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Marisa Winkler, Paul Rhomberg, Kelley Fedler, Samuel Edeker, Abby L Klauer, Mariana Castanheira
Journal journal of the pediatric infectious diseases society
Year 2026
DOI
10.1093/jpids/piag053
URL
https://doi.org/10.1093/jpids/piag053
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.